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AUTHOR'S SUMMARY
We sought to determine neurological outcomes following stroke in patients with left 
atrial appendage occlusion (LAAO) or non-vitamin K antagonist oral anticoagulant 
(NOAC) treatment for non-valvular atrial fibrillation (NVAF). Left atrial appendage closure 
significantly reduced stroke severity and lowered the risk of disabling stroke at 12 months 
post-event compared to NOAC after adjusting for multiple demographic and cardiovascular 
risk factors (odds ratio, 0.23; 95% confidence interval, 0.07–0.71; p=0.01). Thus, LAAO may 
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yield more favorable outcomes in NVAF patients experiencing subsequent stroke than NOAC 
treatment, even in patients with increased risk of cardio- and cerebrovascular events.
ABSTRACT
Background and Objectives: Prior studies have shown that stroke patients treated with 
percutaneous left atrial appendage occlusion (LAAO) for non-valvular atrial fibrillation 
(NVAF) experience better outcomes than similar patients treated with warfarin. We 
investigated the impact of percutaneous left atrial appendage closure on post-stroke 
neurological outcomes in NVAF patients, compared with non-vitamin K antagonist oral 
anticoagulant (NOAC) therapy.
Methods: Medical records for 1,427 patients in multiple registries and for 1,792 consecutive 
patients at 6 Korean hospitals were reviewed with respect to LAAO or NOAC treatment. 
Stroke severity in patients who experienced ischemic stroke or transient ischemic attack 
after either treatment was assessed with modified Rankin Scale (mRS) scoring at hospital 
discharge and at 3 and 12 months post-stroke.
Results: mRS scores were significantly lower in LAAO patients at 3 (p<0.01) and 12 months 
(p<0.01) post-stroke, despite no significant differences in scores before the ischemic 
cerebrovascular event (p=0.22). The occurrences of disabling ischemic stroke in the LAAO and 
NOAC groups were 36.7% and 44.2% at discharge (p=0.47), 23.3% and 44.2% at 3 months 
post-stroke (p=0.04), and 13.3% and 43.0% at 12 months post-stroke (p=0.01), respectively. 
Recovery rates for disabling ischemic stroke at discharge to 12 months post-stroke were 
significantly higher for LAAO patients (50.0%) than for NOAC patients (5.6%) (p<0.01).
Conclusions: Percutaneous LAAO was associated with more favorable neurological outcomes 
after ischemic cerebrovascular event than NOAC treatment.
Keywords: Stroke; Atrial fibrillation; Atrial appendage; Factor Xa inhibitors
INTRODUCTION
Atrial fibrillation (AF)-associated ischemic stroke poses significantly higher morbidity and 
mortality than strokes of vascular origin.1) Cardiac emboli originating from the left atrial 
appendage (LAA) are common causes of ischemic stroke in patients with AF,2) and are 
associated with more severe ischemic stroke and longer transient ischemic attacks (TIAs) 
than strokes secondary to atherosclerotic cerebrovascular disease.3) With the increased risk 
of arterial thromboembolism associated with AF, stroke prevention with oral anticoagulation 
(OAC) is the cornerstone of AF management.4) Non-vitamin K antagonist oral anticoagulants 
(NOACs) are often superior to vitamin K antagonists with respect to efficacy and safety, and 
exhibit more predictable pharmacodynamics and -kinetics, making them less susceptible to 
drug and food interactions and eliminating the need for regular blood monitoring.5) Given 
the safety issues of indefinite OAC use with either approach, LAA occlusion (LAAO) may be 
an alternative strategy for prevention of stroke, systemic embolization, bleeding, and death in 
AF patients taking OACs.6) Recent studies have reported less disabling and lethal strokes after 
percutaneous LAAO with the Amplatzer cardiac plug (ACP; Abbott Vascular, St. Paul, MN, USA) 
or Watchman device (Boston Scientific, Marlborough, MA, USA) than those in patients on 
warfarin therapy.7-9) However, no comparative data regarding ischemic cerebrovascular event-
associated neurological outcomes following percutaneous LAA closure or NOAC treatment are 
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available. This study investigated post-stroke neurological outcomes in non-valvular AF (NVAF) 
patients treated with LAAO, compared to those treated with NOAC therapy.
METHODS
Ethical statement
The study protocol adhered to the ethical guidelines of the 2013 Declaration of Helsinki. Use 
of all registry data was approved by the Institutional Review Board (Approval number: 4-2017-
0343), which waived the requirement for informed consent.
Study population
We performed a multi-center, multi-national retrospective cohort study of ischemic stroke and 
TIA patients who underwent percutaneous LAAO or received NOACs before the index stroke. 
From the medical records of 1,427 consecutive patients in the Korean LAAO registry (May 2013 
to January 2017), European ACP Multi-Center Registry (December 2008 to November 2013), or 
Hong Kong Prince of Wales Hospital LAAO registry (June 2009 to October 2017), we identified 
30 patients who experienced ischemic stroke or TIA during follow-up after LAAO. We enrolled 
86 patients who were treated with NOAC among 1,792 consecutive, acute ischemic stroke 
or TIA patients who were admitted to the neurology departments at 6 hospitals in South 
Korea (Severance Stroke Center, Gangnam Severance Stroke Center, Kyung Hee University 
Hospital Stroke Center, Changwon Fatima Hospital, Inje Paik Hospital, and Pusan National 
University Hospital) within 7 days from stroke onset from January 2013 to December 2016, 
despite NOAC usage among NVAF patients (Figure 1). Exclusion criteria were hemorrhagic or 
periprocedural strokes. In this analysis, we excluded 11 patients who underwent LAA closure 
due to intracranial hemorrhage and periprocedural stroke.
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Figure 1. Overview of study participants and corresponding ischemic events. 
ACP = Amplatzer cardiac plug; AF = atrial fibrillation; LAAO = left atrial appendage occlusion. 
*Ischemic stroke or transient ischemic attack.
Left atrial appendage closure procedure and clinical follow-up
All procedures were performed by experienced operators under transesophageal 
echocardiography (TEE) and fluoroscopy for guidance using ACP and Watchman devices. 
Implanted device size was determined based on LAA angiography and pre-procedural TEE 
according to each device's sizing instructions.
All implanted patients were followed up via scheduled clinical visits at each center, medical 
report review, or telephone interviews. Clinical follow-up was complete in 1,379/1,399 of 
successfully implanted patients (98.6%; European ACP registry, 98.2%; Korean LAAO 
registry, 100%; Hong Kong Prince of Wales hospital registry, 99.1%). Although the 
Watchman and ACP devices were recommended in the duration of anti-coagulation and 
anti-platelet agents, the cessation of antithrombotic treatment after a successful procedure 
was done at the physician's discretion based on individualized risk estimation.6)10) Only 
patients with cerebrovascular events were specifically assessed at each visit for their degree 
of disability in daily activities. To ensure effective LAAO without significant residual leaks, 
the absence of device-related thrombi and erosion of the device with pericardial effusion 
or device embolization was determined through TEE or computed tomography regularly 
performed at least once 3–6 months after the procedure. Significant peri-device leakage was 
defined as that ≥3 and 5 mm for the ACP and Watchman devices, respectively.6)11)
Non-vitamin K antagonist oral anticoagulant treatment and clinical follow-up
Full-dose NOACs (per day) were defined as follows: dabigatran 150 mg twice, apixaban 5 
mg twice, rivaroxaban 20 mg once, and edoxaban 60 mg once. Reduced NOAC doses (per 
day) were defined as follows: dabigatran 110 mg twice, apixaban 2.5 mg twice, rivaroxaban 
15 mg or 10 mg once, and edoxaban 30 mg once. During follow-up, stroke neurologists and/
or research nurses regularly contacted the patients or their caregivers via regular face-to-face 
visits or telephone interviews with/without medical chart review.
Definition and outcomes
All clinical events were adjudicated by 2 cardiologists for the LAAO group and stroke 
neurologists for the NOAC group and were confirmed by a third referee if needed. 
Neurologists in each institution determined the functional outcomes by review of the 
medical records and, face-to-face or telephone interviews after ischemic events. Stroke was 
defined as follows: 1) an acute episode of focal neurological dysfunction caused by brain, 
spinal cord, or retinal vascular injury as a result of infarction; 2) duration of neurological 
dysfunction over 24 hours; 3) duration of neurological dysfunction less than 24 hours due to 
a new imaging-documented infarction; or 4) a neurological dysfunction resulting in death.12) 
TIA was defined as any neurological dysfunction not satisfying the above criteria for stroke, 
such as lasting fewer than 24 hours without an imaging-documented acute brain infarction.12)
We assessed the functional outcome as modified Rankin Scale (mRS) scores before the event, 
at discharge, and at 3 and 12 months after ischemic stroke or TIA. The primary endpoint was 
defined as the rate of disabling ischemic stroke at discharge and at 3 and 12 months post-
stroke. Disabling ischemic stroke were defined as those with a mRS score of 3 to 6.13)
Statistical analysis
Normally distributed continuous variables are expressed as means±standard deviations 
and were compared using Student's t-tests. Non-normally distributed continuous variables 
are reported as medians and interquartile ranges (interquartile range) and were compared 
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using Mann-Whitney U test. Through linear mixed modeling, the mRS scores of 2 groups 
at each point were compared, and mRS scores were also compared by adjusting for various 
confounding factors. Categorical variables are presented as percentile values and were 
compared with χ2 or Fisher's exact tests as appropriate. mRS scores were treated as a 
continuous variable due to its linearity.13) Associations between follow-up disabling ischemic 
stroke at 12 months post-procedure or NOAC treatment were assessed after adjustment 
for multiple risk factors using the logistic regression model with the inverse probability of 
treatment weighting (IPTW).14) All significance tests were 2-tailed, and p values less than 0.05 
indicated statistical significance. All statistical analyses were performed with SPSS statistical 
software (SPSS version 23.0 for Windows; IBM Corp., Armonk, NY, USA).
RESULTS
Baseline and post-procedural parameters
Patient characteristics are presented in Table 1. The overall mean age of the patients was 
73.4±9.3 years (range, 46–89 years), and 46.6% (54/116) of patients were male. Compared 
to stroke patients treated with NOAC, those with LAAO had higher prevalence of diabetes 
mellitus and congestive heart failure. Other baseline and clinical characteristics, including 
incidence of previous stroke or TIA, were similar between the 2 groups. The risks of stroke 
or major bleeding as assessed by CHADS2 (p=0.69), CHA2DS2-VASc (p=0.67), and HAS-BLED 
scores (p=0.75) were also similar between the 2 groups.
Among patients treated with NOACs, 39.5% (34/86) patients received dabigatran, 23.3% 
(20/86) received rivaroxaban, 32.6 (28/86) received apixaban, and 4.7% (4/86) patients 
received edoxaban. The majority of patients (59.3% [51/86]) received reduced doses of 
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Table 1. Baseline characteristics
Variables LAAO (n=30) NOAC (n=86) p value
Age (years) 73.0±10.1 73.5±9.1 0.78
Age ≥65 years 25 (83.3) 68 (79.1) 0.79
Male (sex) 14 (46.7) 40 (46.5) 0.99
Hypertension 28 (93.3) 76 (88.4) 0.73
Diabetes mellitus 17 (56.7) 31 (36.0) 0.048
Congestive heart failure 7 (23.3) 7 (8.1) 0.03
Previous stroke/TIA 14 (46.7) 53 (61.6) 0.15
CHADS2 score 3 (2–4) 3 (2–4) 0.69
CHA2DS2-VASc score 5 (3–6) 5 (4–6) 0.67
HAS-BLED score 3 (2–4) 3 (2–4) 0.75
mRS before the event
mRS 0–1 27 (90.0) 74 (86.0) 0.76
mRS 0–2 28 (93.3) 78 (90.7) 1.00
mRS 0–3 29 (96.7) 81 (94.2) 1.00







Full dose 35 (40.7)
Reduced dose 51 (59.3)
Data are presented as a mean±standard deviation, median (interquartile range), or number (%).
LAAO = left atrial appendage occlusion; mRS = modified Rankin Scale; NOAC = non-vitamin K antagonist oral 
anticoagulant; TIA = transient ischemic attack.
their respective NOAC because of advanced age, low body weight, or elevated creatinine 
level. 37 (43.0%) patients were treated with off-label dose of NOAC. Of the 86 patients who 
experienced stroke after taking NOACs, 19 (22.1%) were taking antiplatelet agents together 
(Supplementary Table 1).
The clinical indications of LAAO procedures in 30 patients with stroke were as follows: 
thromboembolism despite OAC treatment (n=7), previous major bleeding (n=9), high risk 
of bleeding (n=6), triple therapy (n=3), labile international normalized ratio (n=1), and 
patient preference (n=4). Among 30 patients treated with an LAA closure device, 24 (80.0%) 
received an ACP, and 6 (20.0%) received a Watchman device. Routine TEE surveillance was 
recommended at 6–8 weeks post-procedure to evaluate device positioning, the presence 
of device-related thrombosis, and intra- or peri-device leakage. Device thrombosis and 
peri-device leakage occurred in 4 (13.3%) and 3 (10.0%) patients, respectively (Table 2). 
In 2 patients with device thrombosis, the thrombus was not found during routine TEE 
surveillance, but documented at the repeat TEE after the stroke event. The time intervals 
between percutaneous LAA closure and stroke event of the 2 patients with device thrombosis 
were 2,344 and 208 days, respectively.
Cerebrovascular events
The mean intervals (months) from NOAC initiation or percutaneous LAAO to ischemic 
stroke or TIA were 9.9±9.8 and 20.1±20.2 months, respectively. We noted 30 ischemic 
events (2.1%) in the LAAO group (n=1,427), with a composite of 19 strokes and 11 TIAs. In 
the NOAC group (n=858), 85 strokes and one TIA occurred in patients with NVAF. Fourteen 
patients in the LAAO group (14/30, 46.7%) and 53 in the NOAC group (53/86, 61.6%) had 
a history of stroke or TIA (p=0.15). Twenty-three LAAO patients (76.7%) were on single 
antiplatelet therapy when the ischemic event occurred, while only 5 patients were undergoing 
dual antiplatelet therapy at the time of the event. Two patients were taking warfarin due to 
hypertrophic cardiomyopathy with AF, as well as rivaroxaban due to device thrombosis. Of 
the 86 patients in the NOAC group, 2 were treated with an intravenous tissue plasminogen 
activator (tPA) treatment, 13 were treated with endovascular treatment (EVT), and 2 were 
treated with both intravenous tPA and EVT after stoke.
Neurological assessment after ischemic cerebrovascular event
Neurological outcomes according to mRS categories are shown in Supplementary Table 2.  
Estimated mRS scores at discharge (1.8±0.3 vs. 2.7±0.2, p=0.03), 3 months (1.1±0.4 vs. 
2.6±0.2, p<0.01) and at 12 months (1.0±0.4 vs. 2.5±0.2, p<0.01) post-event were lower in 
the LAAO group than in the NOAC group (Table 3). The LAAO group showed similar rates 
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Device thrombosis 4 (13.3)
Watchman 3 (75.0)
ACP 1 (25.0)
Peri-device leakage* 3 (10.0)
Watchman 1 (33.3)
ACP 2 (66.7)
Data are presented as a number (%).
ACP = Amplatzer cardiac plug; LAAO = left atrial appendage occlusion.
*Significant peri-device leakage was defined as ≥3 and 5 mm ACP and Watchman, respectively.
of disabling ischemic stroke at discharge (36.7% vs. 44.2%, p=0.52), compared to the NOAC 
group; however, the disabling ischemic stroke rates at 3 and 12 months post-stroke were 
significantly lower in LAAO patients (3 months: 23.3% vs. 44.2%, p=0.049; 12 months: 13.3% 
vs. 43.0%, p=0.01).
mRS scores between hospital discharge and 12 months post-stroke were significantly reduced 
in the LAAO group (Figure 2). The LAAO group showed a trend toward having a lower 
estimated mRS scores at baseline to those of the NOAC group (p=0.07) and scores at 12 
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Table 3. Stroke burden after adjustments
Variables LAAO (n=30) NOAC (n=86) p value
Before adjustment
mRS before the event 0.3±0.2 0.6±0.1 0.22
mRS at discharge 1.8±0.3 2.7±0.2 0.03
mRS at 3 months 1.1±0.4 2.6±0.2 <0.01
mRS at 12 months 1.0±0.4 2.5±0.2 <0.01
After adjustment
Model 1*
mRS at discharge 1.8±0.3 2.7±0.2 0.03
mRS at 3 months 1.1±0.4 2.6±0.2 <0.01
mRS at 12 months 1.0±0.4 2.5±0.2 <0.01
Model 2*
mRS at discharge 1.8±0.3 2.7±0.2 0.03
mRS at 3 months 1.1±0.4 2.6±0.2 <0.01
mRS at 12 months 1.1±0.4 2.5±0.2 <0.01
Model 3*
mRS at discharge 1.9±0.3 2.6±0.2 0.07
mRS at 3 months 1.2±0.4 2.5±0.2 <0.01
mRS at 12 months 1.1±0.4 2.5±0.2 <0.01
Data are presented as the least square mean±standard error.
LAAO = left atrial appendage occlusion; mRS = modified Rankin Scale; NOAC = non-vitamin K antagonist oral 
anticoagulant.
*Model 1: adjusted for CHA2DS2-VASc score. Model 2: similar to model 1, with the additional inclusion of HAS-BLED 
score. Model 3: similar to model 2, with the additional inclusion of age, gender, and cardiovascular risk factors 














































Figure 2. Comparison of stroke severity in patients treated with LAAO or NOACs. Changes in modified Rankin 
Scale scores of patients from each treatment group at the time of hospital discharge and at the 12-month follow-
up visit are shown. 
LAAO = left atrial appendage occlusion; NOAC = non-vitamin K antagonist oral anticoagulant.
months post-stroke were significantly lower in the LAAO group (p<0.01), even after adjusting 
for several variables, including CHA2DS2-VASc score, HAS-BLED score, age, gender, and other 
cardiovascular risk factors.
Ten patients (2 in the LAAO group and 8 in the NOAC group) showed functional disability 
(mRS >2) before LAA closure or NOAC treatment. After excluding the above 10 patients, 
disabling ischemic stroke developed in 9 (32.1%) of the remaining 28 patients treated with 
LAAO and 30 (38.5%) of the remaining 78 patients treated with NOAC. Two (8.3%) and 29 
(38.7%) patients remained disabled at 12 months after cerebrovascular events in the LAAO 
and NOAC groups, respectively. Similar to the results before excluding 10 patients who had 
previous functional disability, estimated mRS scores at 3 (p<0.01) and 12 months post-stroke 
(p<0.01) were significantly lower in the LAAO group, even after adjusting for several variables, 
including CHA2DS2-VASc score, HAS-BLED score, age, gender, and other cardiovascular risk 
factors (p<0.01). The LAAO group showed a trend toward having a lower estimated mRS 
scores at baseline to those of the NOAC group (p=0.05) (Supplementary Table 3).
Estimated mRS scores at 12 months post-stroke were significantly lower in the LAAO group, 
even after adjusting for several variables, including CHA2DS2-VASc score, HAS-BLED score, 
age, gender, and other cardiovascular risk factors (vs. off-label dose of NOAC; p<0.01, on-
label dose; p=0.01) (Supplementary Tables 4 and 5).
The occurrence of disabling ischemic stroke at 12 months was significantly lower in the 
LAAO group (13.3%) than in the NOAC group (43.0%) (p=0.01). Similarly, recovery rates for 
disabling ischemic stroke at discharge to 12 months post-stroke were significantly higher for 
LAAO patients (50.0%) than for NOAC patients (5.6%) (p<0.01).
Using IPTW, we also evaluated the association between disabling ischemic stroke (mRS 
≥3) and percutaneous LAAO, compared to NOAC treatment, after adjusting for cardiac risk 
factors and CHA2DS2-VASc and HAS-BLED scores. Percutaneous LAAO was significantly 
associated with a lower prevalence of disabling ischemic stroke at 12 months post-stroke 
(odds ratio, 0.23; 95% confidence interval, 0.07–0.64; p=0.01) than with NOAC treatment 
(Supplementary Tables 6 and 7).
DISCUSSION
The principal findings of our study are as follows: 1) the frequency of disabling ischemic 
stroke was lower in NVAF patients treated with LAAO than those treated with NOAC at 3 and 
12 months after discharge; 2) recovery rates from disabling ischemic stroke at discharge to 12 
months post-stroke were significantly greater in LAAO patients; and 3) mRS scores between 
discharge and 12 months post-ischemic cerebrovascular events were significantly reduced 
in the LAAO group. To the best of our knowledge, this is the first clinical study comparing 
the neurological outcomes of NVAF patients with LAAO and NOAC treatment after ischemic 
cerebrovascular events, even after excluding hemorrhagic stroke (Figure 3).
Previous papers have reported less lethal and disabling ischemic stroke after percutaneous 
LAAO than those treated with warfarin.7)9) More recently, we reported that NVAF patients 
previously treated with LAAO experienced more favorable outcomes following ischemic 
cerebrovascular events than patients taking warfarin.8) The prevalence of disabling ischemic 
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stroke were 37.5% and 58.8% at discharge (p=0.07), 20.8% and 42.6% at 3 months (p=0.08), 
and 12.5% and 39.7% at 12 months (p=0.02) in the LAAO and warfarin groups, respectively. 
The mRS was significantly lower in the LAAO group at discharge, 3 months, and 12 months 
after ischemic cerebrovascular events (all p<0.01), despite no significant difference in mRS 
before ischemic cerebrovascular events (p=0.98). Patients in the LAAO group showed a 
significant reduction in mRS between discharge and 12 months (p<0.01), unlike patients 
in the warfarin group (p=0.10). Our current study expounded on favorable neurological 
outcomes of LAAO in patients with ischemic cerebrovascular events in comparison with 
NOAC treatment.
The incidences of ischemic stroke and TIA events were 1.33% (19 out of 1,427) and 0.77% (11 
out of 1,427) in NVAF patients treated with LAAO were markedly low and within acceptable 
limits, especially considering the higher prevalence of previous cerebrovascular events 
(46.7%) and a high CHA2DS2-VASc score of 4.7±1.5 in these patients. Similarly, although 
hemorrhagic stroke was excluded from our formal analysis, the occurrence of intracranial 
hemorrhage events was low, despite relatively high HAS-BLED scores in our study 
participants. Thus, the low incidences of ischemic stroke, TIA, and/or hemorrhagic stroke in 
high-risk patients may be valuable advantages of LAAO over NOAC therapy.
Stroke in AF patients has been extensively associated with higher mortality and greater 
disability.1)2) In this study, after excluding LAAO patients with functional disability before 
the index event, only 2 patients (8.3%) remained disabled at 12 months after discharge, 
compared to 29 NOAC patients (38.7%). Of these patients, 32.1% (9/28) and 38.5% (30/78) of 
the patients in the LAAO and NOAC groups, respectively, presented with severe functional 
disability (mRS >2) at hospital discharge. Moreover, rates of recovery from disabling ischemic 
stroke at 12 months post-event were significantly higher in the LAAO group (66.7%) than in 
the NOAC group (7.1%). Significantly reduced mRS scores between hospital discharge and 
12 months post-stroke were also seen in LAAO patients, but not in NOAC patients. These 
findings corroborate those of the PROTECT-AF trial,15) which reported disabling ischemic 
stroke in 31% (8/26) of patients after LAAO and in 55% (11/20) of patients after warfarin 
treatment with relatively low CHA2DS2-VASc scores. However, some differences between 
the PROTECT-AF study and the current study must be considered: Unlike the PROTECT-AF 
study, our study showed a lower rate of disabling ischemic stroke in LAAO, compared to anti-
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Figure 3. Stroke burden reduction with percutaneous LAAO vs. NOAC treatment. 
LAAO = left atrial appendage occlusion; NOAC = non-vitamin K antagonist oral anticoagulant.
coagulant treatment only, from ischemic stroke and TIA, even after excluding hemorrhagic 
stroke, since hemorrhagic stroke is known to be more prevalent in anticoagulant treatment 
including NOAC. Secondly, the PROTECT-AF study used only the Watchman device for stroke 
prevention, while we included both the Watchman and ACP devices. However, the mRS 
scores post-stroke were not significantly different between the devices in our study, even after 
adjusting for multiple potential risk factors.
The favorable neurological outcomes we observed in LAAO patients may be explained in 
several ways. Stroke severity in NVAF could be affected by the patient characteristics of 
age, risk stratification, stroke mechanism, or prior antithrombotic medication status. In 
this study, there were no differences in age and, CHADS2 or CHA2DS2-VASc scores between 
patients with LAAO and those with NOAC, which implies that the different neurological 
outcomes did not result from different baseline characteristics. Instead, compared to NOAC, 
LAAO could more effectively prevent thrombus formation within the heart, as most strokes 
in NVAF patients are caused by thrombi that originate from LAA and as severe stroke is 
related to larger thrombi in LAA.2) In a previous study, LAA closure was associated with an 
improvement in LA mechanical function,16) a powerful predictor of major cardiovascular 
events.17) In this regard, the neurological outcomes may have been better in patients who 
were treated with LAAO than by NOAC. LAAO has another benefit over anticoagulation in the 
setting of hemorrhagic complications following cerebral infarction in that it does not impact 
hemorrhagic transformation; therefore, anticoagulants would likely lead to more favorable 
neurological outcomes. Although OAC therapy can prevent the formation of intracardiac 
thrombi, its efficacy may be insufficient in patients with higher CHA2DS2-VASc scores or 
previous history of stroke18) On the contrary, the benefit of LAAO was greater in patients 
with higher CHA2DS2-VASc scores or those with previous history of stroke.19) In addition, the 
clinical net benefit of LAAO can be more prominent over 9 months after the procedure.20) Our 
study population had high CHA2DS2-VASc scores or higher proportion of previous stroke, and 
patients in LAAO group were followed up for more than 20 months. These factors could have 
led to more favorable outcomes for LAAO in our study.
Some limitations of our study should be noted. First, this is a retrospective, non-randomized, 
observational study that included a small number of patients, even from 3 multi-center 
registries. Therefore, there were some limitations in collecting detailed information of baseline 
characteristics, as well as comparing outcomes according to different devices and specific 
NOACs or different doses of NOACs. Additionally, the incidences of stroke in these registries 
for both groups were remarkably low because of possible incomplete reporting of stroke. 
Nevertheless, this is the first clinical study reporting the neurological outcomes of NVAF 
patients after treatment with LAAO devices, compared with NOAC therapy. Second, recurrent 
vascular events or hemorrhagic strokes were not analyzed in this study. Third, one should 
consider the different ethnicities between the LAAO group and NOAC groups. Fourth, although 
the degree or types of rehabilitation treatment could be associated with a patient's outcome, 
stroke patients included in this analysis received rehabilitation treatment in various centers, 
and we did not adjust the impact of rehabilitation, which could be another limitation in this 
study. Sixth, we did not compare the infarct size (area or volume in neuroimaging study), but 
we focused on comparing the functional neurological outcome through mRS and proportion 
of disabling ischemic stroke. Finally, in the current study, there was no imaging core lab for the 
acquisition and analysis of images. However, as a manner of multi-center registry, the analysis 
of echocardiographic images was performed by imaging specialists at each participating center, 
and all assessments of images were conducted following the generally recommended protocol.10)
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In conclusion, percutaneous LAAO yielded favorable neurological outcomes, compared 
with NOAC, in patients who experienced ischemic cerebrovascular events. These findings 
suggest an increased neurological benefit of LAAO over NOAC use for long-term protection 
against thrombus formation in NVAF patients, including those at higher risk of cardio- and 
cerebrovascular events.
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